tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMVT Stock Latest News

Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength
Company AnnouncementsImmunovant’s Earnings Call Highlights Clinical Success and Financial Strength
2d ago
IMVT
Immunovant’s Promising Clinical Progress and Market Potential Justifies Buy Rating
PremiumRatings
Immunovant’s Promising Clinical Progress and Market Potential Justifies Buy Rating
3d ago
IMVT
Immunovant Reports Q2 2025 Financials and Clinical Progress
PremiumCompany Announcements
Immunovant Reports Q2 2025 Financials and Clinical Progress
3d ago
IMVT
Immunovant reports Q2 EPS (73c), consensus (73c)
PremiumThe Fly
Immunovant reports Q2 EPS (73c), consensus (73c)
3d ago
IMVT
Is IMVT a Buy, Before Earnings?
PremiumPre-Earnings
Is IMVT a Buy, Before Earnings?
6d ago
IMVT
Immunovant rumor highlighted in Betaville alert
PremiumThe FlyImmunovant rumor highlighted in Betaville alert
14d ago
IMVT
Immunovant initiated with a Hold at Truist
Premium
The Fly
Immunovant initiated with a Hold at Truist
1M ago
IMVT
Immunovant price target lowered to $33 from $37 at JPMorgan
Premium
The Fly
Immunovant price target lowered to $33 from $37 at JPMorgan
1M ago
IMVT
3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
2M ago
IVA
IMVT
Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
PremiumRatings
Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
2M ago
IMVT
Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
PremiumRatings
Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
2M ago
IMVT
Immunovant Announces Promising Graves’ Disease Study Results
PremiumCompany Announcements
Immunovant Announces Promising Graves’ Disease Study Results
2M ago
8K
IMVT
Immunovant: 80% of patients demonstrate response in Graves’ disease trial
PremiumThe FlyImmunovant: 80% of patients demonstrate response in Graves’ disease trial
2M ago
IMVT
Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
Premium
Ratings
Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
3M ago
IMVT
Immunovant Stockholders Approve Key Governance Decisions
Premium
Company Announcements
Immunovant Stockholders Approve Key Governance Decisions
3M ago
8K
IMVT
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
PremiumRatings
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
3M ago
IMVT
Immunovant price target lowered to $30 from $33 at BofA
PremiumThe Fly
Immunovant price target lowered to $30 from $33 at BofA
3M ago
IMVT
Immunovant price target lowered to $37 from $40 at JPMorgan
PremiumThe Fly
Immunovant price target lowered to $37 from $40 at JPMorgan
3M ago
IMVT
Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
PremiumRatings
Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
3M ago
IMVT
Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
PremiumRatingsImmunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
3M ago
IMVT
Immunovant Reports Progress and Financial Results
Premium
Company Announcements
Immunovant Reports Progress and Financial Results
3M ago
IMVT
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
Premium
Ratings
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
3M ago
IMVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >